KR950700056A - 분무-냉각된 나부메톤(Spray-chilled nabumetone) - Google Patents

분무-냉각된 나부메톤(Spray-chilled nabumetone)

Info

Publication number
KR950700056A
KR950700056A KR1019940702615A KR19940702615A KR950700056A KR 950700056 A KR950700056 A KR 950700056A KR 1019940702615 A KR1019940702615 A KR 1019940702615A KR 19940702615 A KR19940702615 A KR 19940702615A KR 950700056 A KR950700056 A KR 950700056A
Authority
KR
South Korea
Prior art keywords
spray
cooled
nabumethone
nabumetone
dosage form
Prior art date
Application number
KR1019940702615A
Other languages
English (en)
Inventor
스탠리 레너드 그레이엄
Original Assignee
브라이언 존 러셀
스미스클라인 비이참 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브라이언 존 러셀, 스미스클라인 비이참 피이엘시이 filed Critical 브라이언 존 러셀
Publication of KR950700056A publication Critical patent/KR950700056A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coating By Spraying Or Casting (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Freezing, Cooling And Drying Of Foods (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catching Or Destruction (AREA)
  • Road Signs Or Road Markings (AREA)

Abstract

분무-냉각되고 종전의 가능했던 부피보다 작은 부피를 갖는 단위 복용 형태로 배향된 나부메톤

Description

분무-냉각된 나부메톤(Spray-chilled nabumetone)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (14)

  1. 분무-냉각된 나부메톤.
  2. 성입 밀도 범위 0.40-0.6g5cm-3를 갖는 분무-냉각된 나부메톤.
  3. 탭 밀도 범위 0.50-0.65gcm-3를 갖는 분무-냉각된 나부메톤.
  4. 제약학적으로 허용가능한 부형제와 혼합된 제1-3항중 임의의 한 항에 따른 분무 냉각된 나부메톤을 함유한 제약학적 조성물.
  5. 제1-4항중 임의의 한 항에 따른 분무-냉각된 나부메톤의 단위 복용 형태.
  6. 제5항에 있어서, 종래의 보형제와 혼합된 분무-냉각된 나부메톤 500mg을 함유한, 0.480㎤ 미만의 부피를 갖는 연하 정제인 단위 복용 형태.
  7. 제5항에 있어서, 보형제와 혼합된 분무-냉각된 나부메톤 1000mg을 함유한, 0.960㎤ 미만의 부피를 갖는 연하 정제인 단위 복용 형태.
  8. 제5-7항중 임의 한 항에 있어서, 보형제로서 충진제를 갖지 않거나 실질적으로 갖지 않는 단위 복용 형태.
  9. 분무-냉각된 나부메톤 대 보형제의 백분율(중량/중량)이 82% 이상인 제6-8항중 임의의 한 항에 따른 연하 정제.
  10. 제9항에 있어서, 분무-냉각된 나부메톤 대 보형제의 백분율이 90%이상인 연하 정제.
  11. 고체 나부메톤을 용융시키고, 그를 분무-급냉기를 갖는 급냉기-실내로 분무시키고, 결과 얻어진 생성물을 수집하는 것으로 구성된 분무-냉각된 나부메톤 제조 방법.
  12. 제1-11항중 임의의 한 항에 따른 유효량의 분무-냉각된 나부메톤을 그를 필요로 하는 환자에게 투여하는 것으로 구성되는 염증, 염좌, 좌상, 암통증, 열병, 오에스테오포로시스 및 안면근 통증 증후군의 치료 방법.
  13. 염증, 염좌, 좌상, 암통증, 열병, 오에스테오포로시스 및 안면근 통증 증후군의 치료를 위한 약제를 제조하는데 제1-11항중 임의의 한 항에 따른 분무-냉각된 나부메톤의 사용.
  14. 실시예 2 및 3을 참고하여 본원에 실질적으로 서술된 바와 같은 분무-냉각된 나부메톤을 함유한 단위 복용 형태.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940702615A 1992-01-29 1993-01-22 분무-냉각된 나부메톤(Spray-chilled nabumetone) KR950700056A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9201857.1 1992-01-29
GB929201857A GB9201857D0 (en) 1992-01-29 1992-01-29 Novel compound
PCT/GB1993/000145 WO1993014747A1 (en) 1992-01-29 1993-01-22 Spray-chilled nabumetone

Publications (1)

Publication Number Publication Date
KR950700056A true KR950700056A (ko) 1995-01-16

Family

ID=10709436

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940702615A KR950700056A (ko) 1992-01-29 1993-01-22 분무-냉각된 나부메톤(Spray-chilled nabumetone)

Country Status (24)

Country Link
US (1) US5539000A (ko)
EP (1) EP0624087B1 (ko)
JP (1) JPH07503245A (ko)
KR (1) KR950700056A (ko)
CN (1) CN1079954A (ko)
AT (1) ATE150298T1 (ko)
AU (1) AU3362693A (ko)
BG (1) BG98933A (ko)
BR (1) BR9305674A (ko)
CA (1) CA2129027A1 (ko)
CZ (1) CZ182894A3 (ko)
DE (1) DE69309037T2 (ko)
DK (1) DK0624087T3 (ko)
ES (1) ES2099419T3 (ko)
FI (1) FI943550A0 (ko)
GB (1) GB9201857D0 (ko)
GR (1) GR3023142T3 (ko)
HU (1) HUT67462A (ko)
IL (1) IL104526A0 (ko)
MX (1) MX9300430A (ko)
NO (1) NO942813L (ko)
SK (1) SK91694A3 (ko)
WO (1) WO1993014747A1 (ko)
ZA (1) ZA93577B (ko)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920148D0 (en) * 1999-08-25 1999-10-27 Smithkline Beecham Plc Novel composition
US6552078B2 (en) 1999-10-27 2003-04-22 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
TWI262791B (en) 1999-10-27 2006-10-01 Nobex Corp 6-methoxy-2-naphthylacetic acid prodrugs
US6436990B1 (en) 1999-10-27 2002-08-20 Nobex Corporation 6-methoxy-2-naphthylacetic acid prodrugs
US20020132010A1 (en) * 2000-12-22 2002-09-19 Yihong Qui Divalproex sodium dosage forms and a process for their production
US20040161474A1 (en) * 2002-05-24 2004-08-19 Moerck Rudi E. Rare earth metal compounds methods of making, and methods of using the same
US20060083791A1 (en) 2002-05-24 2006-04-20 Moerck Rudi E Rare earth metal compounds methods of making, and methods of using the same
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
WO2005053640A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Azithromycin multiparticulate dosage forms by liquid-based processes
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
ATE399536T1 (de) * 2003-12-04 2008-07-15 Pfizer Prod Inc Verfahren zur herstellung von pharmazeutischen multiteilchenförmigen produkten
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
JP2008516971A (ja) * 2004-10-15 2008-05-22 アルテアーナノ，インコーポレーテッド 錠剤による負荷が軽減されるリン酸塩結合剤
JP2009504779A (ja) * 2005-08-17 2009-02-05 アルテアナノ インコーポレイテッド 家畜における慢性腎不全及びその他の病気の治療：組成物及び方法
US7541384B2 (en) * 2007-06-08 2009-06-02 Axcan Pharma Inc. Mesalamine suppository
US8436051B2 (en) 2007-06-08 2013-05-07 Aptalis Pharma Canada Inc. Mesalamine suppository
US8217083B2 (en) * 2007-06-08 2012-07-10 Aptalis Pharma Canada Inc. Mesalamine suppository
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
EP3848040A1 (en) 2010-05-12 2021-07-14 Spectrum Pharmaceuticals, Inc. Lanthanum dioxycarbonate and use
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
CA3078723A1 (en) 2016-11-28 2018-05-31 Nachiappan Chidambaram Oral testosterone undecanoate therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1474377A (en) 1973-09-11 1977-05-25 Beecham Group Ltd Naphthalene derivatives
US4420639C1 (en) * 1973-09-11 2001-08-21 Beecham Group Ltd Aromatic compounds
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
DE3833446A1 (de) 1988-10-01 1990-04-05 Hoechst Ag Verfahren zur herstellung von arzneimittelwirkstoff-partikeln mit verbesserten fliess-, lager- und formulierungseigenschaften sowie arzneimittel, die diese arzneimittelwirkstoff-partikeln enthalten

Also Published As

Publication number Publication date
ES2099419T3 (es) 1997-05-16
DE69309037D1 (de) 1997-04-24
SK91694A3 (en) 1995-03-08
JPH07503245A (ja) 1995-04-06
CZ182894A3 (en) 1995-02-15
NO942813D0 (no) 1994-07-28
BR9305674A (pt) 2005-01-11
FI943550A (fi) 1994-07-28
AU3362693A (en) 1993-09-01
IL104526A0 (en) 1993-05-13
DK0624087T3 (da) 1997-09-01
HU9402221D0 (en) 1994-09-28
GR3023142T3 (en) 1997-07-30
CN1079954A (zh) 1993-12-29
MX9300430A (es) 1994-08-31
ZA93577B (en) 1994-01-13
NO942813L (no) 1994-07-28
FI943550A0 (fi) 1994-07-28
ATE150298T1 (de) 1997-04-15
EP0624087A1 (en) 1994-11-17
WO1993014747A1 (en) 1993-08-05
BG98933A (en) 1995-07-28
CA2129027A1 (en) 1993-08-05
HUT67462A (en) 1995-04-28
EP0624087B1 (en) 1997-03-19
DE69309037T2 (de) 1997-07-24
US5539000A (en) 1996-07-23
GB9201857D0 (en) 1992-03-18

Similar Documents

Publication Publication Date Title
KR950700056A (ko) 분무-냉각된 나부메톤(Spray-chilled nabumetone)
GEP20043216B (en) Orally Administered Controlled Drug Delivery System
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
MXPA02012666A (es) Formulaciones farmaceuticas topicas y metodos de tratamiento.
RU98111594A (ru) Фармацевтические композиции, включающие флурбипрофен
NO975334D0 (no) Anvendelse av flavanolignaner for fremstilling av medikamenter med antiproliferativ aktivitet i uterus, ovarium og bryst
BR0108379A (pt) Composições de liberação controlada contendo agonista e antagonista opióide, método para a preparação de uma formulação em dosagem de analgésico opióide de liberação controlada com potência analgésica aumentada e sistema de administração através da derme para um analgésico opióide
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
AU1877992A (en) Linsidomin for treating erectile dysfunctions
KR950703951A (ko) 광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통과 해열치료에 이를 사용하는 방법(antipyretic and analgesic methods and compositions containing optically pure r-ketorolac)
KR930007441A (ko) 의약품
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
NO20030897D0 (no) Fremgangsmåte for fremstilling av farmasöytiske sammensetninger for anvendelse med blöte gelatin formuleringer
ES2125324T3 (es) Film para suministro local de un farmaco para un tratamiento periodontal.
KR960700063A (ko) 사람 종양 세포내에서의 테모졸로마이드의 강화방법(Potentiation of temozolomide in human tumour cells)
JP2001510795A5 (ko)
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
EP1201246A3 (en) Use of Thrombopoietin as a medicament for the therapy and prevention of thrombocytopenia
HUP9901890A2 (hu) Gyógyszer és eljárás szervezet gyógyszeres kezelésére
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
MY124465A (en) Reduction of infarct volume using citicoline
WO1991002529A2 (en) Product and method for killing abnormal vertebrate cells
IL112288A (en) Use of riluzole in the manufacture of a medicament for the treatment of mitochondrial diseases
DE3263832D1 (en) Gallium chloride, an anti-cancer drug

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid